Radiopharmaceuticals: all 1,299 studies that test it
Page 2 of 13. Open to participants first (296), then studies with results posted, then the rest; newest registration first within each.
- An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion TechniqueRecruitingNCT06865768Phase 2
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCRecruitingNCT06855277Phase 3
- An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN TrialRecruitingNCT06813898Early Phase 1
- First-in-Human Study of ADCE-D01 in Soft Tissue SarcomaRecruitingNCT06797999Phase 1/2
- Radiopharmaceutical Treatment of Advanced Kidney CancerRecruitingNCT06783348Phase 2
- Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyRecruitingNCT06780670Phase 2/3
- IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCLRecruitingNCT06768905Phase 1/2
- A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver CancerRecruitingNCT06764316Phase 1
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP StudyRecruitingNCT06750419Phase 3
- Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate CancerRecruitingNCT06738303Phase 2
- Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCCRecruitingNCT06726161Phase 1/2
- The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer PatientsEnrolling by invitationNCT06723665Not applicable
- An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain TumorsRecruitingNCT06667726Phase 2
- Study on the Safety and Efficacy of Sodium Phosphate Powder for Intestinal Preparation in People Aged 50 to 70 Years OldRecruitingNCT06652906Phase 2
- Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human BodyRecruitingNCT06645691Phase 2
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingNCT06632977Phase 2
- Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of GlioblastomaRecruitingNCT06613841Early Phase 1
- Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast CancerRecruitingNCT06611891Phase 3
- Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/2
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and TauNot yet recruitingNCT06600880Phase 1
- STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate CancerRecruitingNCT06574880Phase 1/2
- Preoperative Planning With PSMA-PET in Melanoma Surgery TrialRecruitingNCT06560905Phase 2
- Advanced Imaging for Pulmonary FibrosisRecruitingNCT06532071Phase 2
- Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing DiseaseRecruitingNCT06526299Phase 2
- PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyRecruitingNCT06522932Phase 1
- Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid CarcinomaRecruitingNCT06520319Phase 1
- A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking SurgeryRecruitingNCT06504147Phase 2
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
- Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)RecruitingNCT06496581Phase 3
- Study With [225Ac]Ac-FL-020 in mCRPC ParticipantsRecruitingNCT06492122Phase 1
- PET/MRI to Stage Prostate Cancer PatientsRecruitingNCT06484361Phase 2
- Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate CancerRecruitingNCT06474806Phase 2
- 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate CancerRecruitingNCT06449781Phase 2
- An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney CancerRecruitingNCT06447103Phase 2
- An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With GliomaRecruitingNCT06444412Phase 2
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsRecruitingNCT06441331Phase 1
- 68Ga-AAZTA-093 PET/CT: First-in-human StudyRecruitingNCT06437496Early Phase 1
- Clinical Study of 18F-Alfatide Injection PET/CTNot yet recruitingNCT06416852Phase 3
- 177Lu-DOTATATE Modified Delivery Based on Individualized DosimetryRecruitingNCT06395402Phase 2
- PET Imaging Study of 68Ga-NB381 in Multiple MyelomaRecruitingNCT06385652Early Phase 1
- 177Lu-DOTATATE for Recurrent MeningiomaRecruitingNCT06326190Phase 2
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsRecruitingNCT06305962Early Phase 1
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract CancerRecruitingNCT06298916Phase 1/2
- Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA TrialRecruitingNCT06288113Phase 2
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingNCT06287944Phase 1
- Study of AZD0754 in Participants With Metastatic Prostate CancerRecruitingNCT06267729Phase 1/2
- Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast CancerRecruitingNCT06260033Phase 2
- Neoadjuvant PSMA-RLT in Oligometastatic PCaRecruitingNCT06259123Phase 2
- Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and HypercortisolismRecruitingNCT06246357Phase 2
- PSMA-RLT in Biochemically Recurrent PCaRecruitingNCT06220188Phase 2
- First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingNCT06217822Phase 1
- Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)RecruitingNCT06216249Phase 2
- A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid TumorsRecruitingNCT06211647Phase 1
- A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid TumorsRecruitingNCT06197139Phase 1
- 99mTc-ABH2 SPECT/CT in Breast CancerRecruitingNCT06194565Not applicable
- Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerRecruitingNCT06145633Phase 2
- Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed IndicationsNot yet recruitingNCT06121271Phase 2
- 18F-Fluciclovine PET/CT in Multiple MyelomaRecruitingNCT06103838Phase 2
- Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain InjuryRecruitingNCT06103201Phase 1
- Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide TetraxetanRecruitingNCT06099093Phase 4
- Application of 68Ga-Pentixafor PET/CT for ThymomaRecruitingNCT06086327Early Phase 1
- NeoAdjuvant Theranostic Lutetium Study: The Nautilus TrialRecruitingNCT06066437Phase 1/2
- Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CTRecruitingNCT06062745Phase 1
- Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate CancerNot yet recruitingNCT06062355Phase 1
- Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomyRecruitingNCT06056830Phase 3
- Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate CancerRecruitingNCT06054789Not applicable
- 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic RadiosurgeryRecruitingNCT06048094Phase 1
- "Receptor Radionuclide Therapy With 177Lu-DOTATOCRecruitingNCT06045260Phase 2
- PSMA PET Response Guided SabR in High Risk PcaRecruitingNCT06044857Phase 1
- Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT06016855Phase 4
- Feasibility of Acquiring Hyperpolarized Imaging in Patients With MeningiomaRecruitingNCT06014905Phase 1
- Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid TumorsRecruitingNCT06014658Phase 1/2
- 68Ga-FAPI-04 PET Imaging in Early Response Evaluation of Rectal Cancer Patients Treated With ImmunotherapyRecruitingNCT05999227Not applicable
- 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast CancerRecruitingNCT05982496Phase 2
- Clinical Application of 18F-PFPN PET Imaging in Diagnosis and Staging of Clear Cell Sarcoma of Soft TissueRecruitingNCT05963035Not applicable
- Characterizing Myositis With 68Ga-FAPI PET/CTRecruitingNCT05952531Early Phase 1
- 68Ga-P3 PET/CT Imaging in ProstateRecruitingNCT05940259Not applicable
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.RecruitingNCT05939414Phase 3
- Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal TherapyRecruitingNCT05919329Phase 4
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.RecruitingNCT05918302Phase 3
- Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)RecruitingNCT05893381Phase 2
- Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple MyelomaRecruitingNCT05892393Phase 1
- 64Cu/68Ga Labelled EB-ss-CPT PET/CT Scan in Colorectal CancerRecruitingNCT05891028Early Phase 1
- 64Cu-GRIP B in Patients With Advanced MalignanciesRecruitingNCT05888532Phase 1/2
- 68Ga-P3 PET/CT Imaging in MalignancyRecruitingNCT05887687Not applicable
- Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal LeukoencephalopathyRecruitingNCT05849467Phase 1
- 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsRecruitingNCT05847348Phase 3
- Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer PatientsRecruitingNCT05841992Phase 2/3
- B-amyloid as a Marker for GBM BioimagingNot yet recruitingNCT05820191Phase 2
- A Study of Imaging in Demyelinating DiseasesEnrolling by invitationNCT05805839Phase 2
- Hyperpolarized 13C MRI for Cancer ImmunotherapyNot yet recruitingNCT05805358Phase 2
- Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerRecruitingNCT05803941Phase 4
- Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical ManagementRecruitingNCT05799248Phase 3
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingNCT05773274Phase 2
- Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerRecruitingNCT05766371Phase 2
- Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast CancerRecruitingNCT05736367Not applicable
- Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine NeoplasmsEnrolling by invitationNCT05709171Phase 2
- A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsRecruitingNCT05706129Phase 1/2
- HP Pyruvate MRI in CancersRecruitingNCT05697406Phase 1/2
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsRecruitingNCT05691465Phase 2